✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Orphan Drugs Market Research Report Information By Drug Type (Biologics & Non-Biologics), By Sale (Generics & Prescribed), By Drug (Revlimid, Rituxan, Opdivo, Keytruda, Imbruvica, Soliris, Jakaf, Pomalyst, Darzalex, Spinraza, and Adcetris), By Therapy Class (Oncology, Blood, Central Nervous Systems, Endocrine, Cardiovascular, and Respiratory), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032


ID: MRFR/Pharma/1697-CR | 159 Pages | Author: Kinjoll Dey| March 2019

Market Segmentation for Orphan Drugs Market


Orphan Drugs Drug Type Outlook (USD Billion, 2018-2030)




  • Biologics




  • Non-Biologics




Orphan Drugs Sale Outlook (USD Billion, 2018-2030)




  • Generics




  • Prescribed




Orphan Drugs Drug Outlook (USD Billion, 2018-2030)




  • Revlimid




  • Rituxan




  • Opdivo




  • Keytruda 




  • Imbruvica 




  • Soliris 




  • Jakaf 




  • Pomalyst 




  • Darzalex 




  • Spinraza 




  • Adcetris 




Orphan Drugs Therapy Class Outlook (USD Billion, 2018-2030)




  • Oncology




  • Blood




  • Central Nervous Systems




  • Endocrine 




  • Cardiovascular 




  • Respiratory 




Orphan Drugs Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • North America Orphan Drugs by Sale




      • Generics




      • Prescribed






    • North America Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • North America Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • US Outlook (USD Billion, 2018-2030)




    • US Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • US Orphan Drugs by Sale




      • Generics




      • Prescribed






    • US Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • US Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Canada Outlook (USD Billion, 2018-2030)




    • Canada Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Canada Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Canada Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Canada Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 








  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Europe Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Europe Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Europe Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Germany Outlook (USD Billion, 2018-2030)




    • Germany Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Germany Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Germany Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Germany Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • France Outlook (USD Billion, 2018-2030)




    • France Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • France Orphan Drugs by Sale




      • Generics




      • Prescribed






    • France Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • France Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • UK Outlook (USD Billion, 2018-2030)




    • UK Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • UK Orphan Drugs by Sale




      • Generics




      • Prescribed






    • UK Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • UK Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Italy Outlook (USD Billion, 2018-2030)




    • Italy Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Italy Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Italy Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Italy Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Spain Outlook (USD Billion, 2018-2030)




    • Spain Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Spain Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Spain Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Spain Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Rest Of Europe Outlook (USD Billion, 2018-2030)




    • Rest Of Europe Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Rest Of Europe Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Rest Of Europe Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Rest Of Europe Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 








  • Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Asia-Pacific Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Asia-Pacific Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Asia-Pacific Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Asia-Pacific Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • China Outlook (USD Billion, 2018-2030)




    • China Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • China Orphan Drugs by Sale




      • Generics




      • Prescribed






    • China Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • China Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Japan Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Japan Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Japan Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • India Outlook (USD Billion, 2018-2030)




    • India Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • India Orphan Drugs by Sale




      • Generics




      • Prescribed






    • India Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • India Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Australia Outlook (USD Billion, 2018-2030)




    • Australia Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Australia Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Australia Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Australia Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • South Korea Outlook (USD Billion, 2018-2030)




    • South Korea Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • South Korea Orphan Drugs by Sale




      • Generics




      • Prescribed






    • South Korea Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • South Korea Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Rest of Asia-Pacific Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Rest of Asia-Pacific Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Rest of Asia-Pacific Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Rest of Asia-Pacific Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 








  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Rest of the World Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Rest of the World Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Rest of the World Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Middle East Outlook (USD Billion, 2018-2030)




    • Middle East Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Middle East Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Middle East Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Middle East Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Africa Outlook (USD Billion, 2018-2030)




    • Africa Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Africa Orphan Drugs by Sale




      • Generics




      • Prescribed






    • Africa Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Africa Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 






    • Latin America Outlook (USD Billion, 2018-2030)




    • Latin America Orphan Drugs by Drug Type




      • Biologics




      • Non-Biologics






    • Latin America Orphan Drugs by Sale




      • Generics




      • Prescribe






    • Latin America Orphan Drugs by Drug




      • Revlimid




      • Rituxan




      • Opdivo




      • Keytruda 




      • Imbruvica 




      • Soliris 




      • Jakaf 




      • Pomalyst 




      • Darzalex 




      • Spinraza 




      • Adcetris 






    • Latin America Orphan Drugs by Therapy Class




      • Oncology




      • Blood




      • Central Nervous Systems




      • Endocrine 




      • Cardiovascular 




      • Respiratory 







Research Methodology on Orphan Drugs Market


1. Introduction


This research methodology outlines the methods and approaches applied in the study of the orphan drugs market, as highlighted by Market Research Future in its report. This methodology explains the components of the research design, data collection procedure, sampling technique, and data analysis and interpretation. The analysis of the global orphan drugs market involves a thorough assessment of the key stakeholders, industry trends, current and evolving market dynamics, and drivers and restraints that are expected to directly and/or indirectly impact the market’s growth during the assessment period (2023-2030).


2. Research Design


To collect necessary information, a qualitative and quantitative research design is employed in the market study. The objective of the market study is to size, forecast and analyze the global orphan drugs market for 2023-2030. For this purpose, Market Research Future conducted primary and secondary research on the global orphan drugs market, applying several methodologies such as surveys, technological advancements, etc.


3. Data Collection Procedure


Primary research is conducted through face-to-face, telephonic, and online interviews with industry participants such as CEOs, CFOs, market analysts and regional managers. Data from industry experts and opinion leaders are used to develop a fresh perspective on the market. Industry experts, articles, press releases, white papers, and webinars are used to gather secondary data about the orphan drugs market.


The primary research investors were able to validate the accuracy and complement the secondary research findings. Additionally, the inputs and opinions collected from the end-users, distributors, consultations, and research experts provide comprehensive insights into the global market.


4. Sampling Methodology


The market study is conducted in the following six segments: type, mode of administration, therapeutic application, route of delivery, indications, and region. Under the type segment, monoclonal antibodies, proteins, small molecules and others are studied; and according to the mode of administration segment, oral, parenteral, and others are studied. Additionally, the therapeutic application segment is divided into oncology, rare genetic diseases, rare metabolic diseases, and others; the route of the delivery segment is divided into chronic and acute; the indications segment is divided into rare endocrine disorders, gastroenterological diseases, infections, musculoskeletal disorders, and other indications.


The market is studied in four regions: North America, Europe, Asia-Pacific, and the rest of the world.


5. Data Analysis and Interpretation


In the market study, Market Research Future employed Porter’s five forces analysis, market segmentation, market attractiveness analysis, and value chain analysis. These tools and techniques are used to analyze the orphan drugs market. Additionally, spreadsheets, databases, and MS Office tools are used to analyze the collected data and generate useful insights.


To draw conclusions and make recommendations, Market Research Future conducted interviews with industry players and developed an in-depth analysis of the overall orphan drugs market. The market is segmented and analyzed based on the primary and secondary segmentation variables to identify various trends and insights, which in turn helped shape the market forecast. The market report is further validated using a triangulation method.


Overall, the data collection and analysis procedure is conducted using the most up-to-date data sources and primary and secondary research inputs from industry experts. The resulting market report offered comprehensive insights into the overall orphan drugs market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 18

3.2 Scope of the Study 18

3.3 Assumptions & Limitations 18

3.3.1 Assumptions 18

3.3.2 Limitations 18

3.4 Market Structure 19

4 Research Methodology

4.1 Research Process 21

4.2 Primary Research 22

4.3 Secondary Research 23

4.4 Market Size Estimation 24

4.5 Forecast Model 24

5 Market Dynamics

5.1 Introduction 26

5.2 Drivers 27

5.2.1 Rising prevalence of rare diseases 27

5.2.2 Growing investment in research and development of orphan drugs 27

5.2.3 Increasing awareness regarding rare disorders 28

5.3 Restraints 28

5.3.1 High costs of drugs 28

5.3.2 Competition from generics and biosimilars 28

5.4 Opportunities 29

5.4.1 Development of new technologies 29

6 Market Factor Analysis

6.1 Porters Five Forces Analysis 31

6.1.1 Bargaining Power of Suppliers 31

6.1.2 Bargaining Power of Buyers 31

6.1.3 Threat of New Entrants 32

6.1.4 Threat of Substitutes 32

6.1.5 Intensity of Rivalry 32

6.2 Supply Chain Analysis 33

6.2.1 R&D 33

6.2.2 Manufacturing 33

6.2.3 Distribution 33

6.2.4 Marketing & Sales 33

6.2.5 Post-Sales Monitoring 33

7 Orphan Drugs Market, by Drug Type

7.1 Overview 35

7.1.1 Biologics 36

7.1.2 Non-Biologics 37

8 Orphan Drugs Market, by Sale

8.1 Overview 39

8.1.1 Generics 40

8.1.2 Prescribed 41

9 Orphan Drugs Market, by Drug

9.1 Overview 43

9.1.1 Revlimid 45

9.1.2 Rituxan 45

9.1.3 Opdivo 46

9.1.4 Keytruda 46

9.1.5 Imbruvica 47

9.1.6 Soliris 47

9.1.7 Jakaf 48

9.1.8 Pomalyst 48

9.1.9 Darzalex 49

9.1.10 Spinraza 49

9.1.11 Adcetris 50

10 Orphan Drugs Market, by Therapy Class

10.1 Overview 52

10.1.1 Oncology 54

10.1.2 Blood 54

10.1.3 Central Nervous Systems 55

10.1.4 Endocrine 55

10.1.5 Cardiovascular 56

10.1.6 Respiratory 56

11 Global Orphan Drugs Market, by Region

11.1 Overview 58

11.2 Americas 60

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.2.1 North America 63

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.2.1.1 US 66

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.2.1.2 Canada 68

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.2.2 Latin America 70

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3 Europe 73

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1 Western Europe 77

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1.1 Germany 80

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1.2 France 83

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1.3 UK 85

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1.4 Italy 87

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1.5 Spain 89

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.1.6 Rest of Western Europe 91

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.3.2 Eastern Europe 94

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4 Asia-Pacific 97

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4.1 Japan 100

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4.2 China 102

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4.3 India 104

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4.4 South Korea 106

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4.5 Australia 108

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.4.6 Rest of Asia-Pacific 110

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.5 Middle East & Africa 113

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.5.1 Middle East 116

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

11.5.2 Africa 118

Orphan Drugs Market, by Drug Type

Orphan Drugs Market, by Sale

Orphan Drugs Market, by Drug

Orphan Drugs Market, by Therapy Class

12 Competitive Landscape

12.1 Introduction 122

12.2 Company Share Analysis 122

13 Company Profiles

13.1 F. Hoffmann-La Roche AG 125

13.1.1 Company Overview 125

13.1.2 Financial Overview 125

13.1.3 Products/Services Offered 126

13.1.4 Key Developments 126

13.1.5 SWOT Analysis 126

13.1.6 Key Strategy 126

13.2 Mylan 127

13.2.1 Company Overview 127

13.2.2 Financial Overview 127

13.2.3 Products/Services Offered 128

13.2.4 Key Developments 128

13.2.5 SWOT Analysis 128

13.2.6 Key Strategy 128

13.3 Celgene Corporation 129

13.3.1 Company Overview 129

13.3.2 Financial Overview 129

13.3.3 Products/Services Offered 130

13.3.4 Key Developments 130

13.3.5 SWOT Analysis 130

13.3.6 Key Strategy 130

13.4 Novartis AG 131

13.4.1 Company Overview 131

13.4.2 Financial Overview 131

13.4.3 Products/Services Offered 132

13.4.4 Key Developments 132

13.4.5 SWOT Analysis 132

13.4.6 Key Strategy 132

13.5 Biogen 133

13.5.1 Company Overview 133

13.5.2 Financial Overview 133

13.5.3 Products/Services Offered 134

13.5.4 SWOT Analysis 134

13.5.5 Key strategy 134

13.6 Takeda Pharmaceutical Company Limited 135

13.6.1 Company Overview 135

13.6.2 Financial Overview 135

13.6.3 Products/Services Offered 136

13.6.4 Key Developments 136

13.6.5 SWOT Analysis 136

13.6.6 Key strategy 136

13.7 Merck KGaA 137

13.7.1 Company Overview 137

13.7.2 Financial Overview 137

13.7.3 Products/Services Offered 138

13.7.4 Key Developments 138

13.7.5 SWOT Analysis 138

13.7.6 Key Strategy 138

13.8 Eli Lilly and Company 139

13.8.1 Company Overview 139

13.8.2 Financial Overview 139

13.8.3 Products/Services Offered 140

13.8.4 Key Developments 140

13.8.5 SWOT Analysis 140

13.8.6 Key strategy 140

13.9 Shire Pharmaceutical 141

13.9.1 Company Overview 141

13.9.2 Financial Overview 141

13.9.3 Products/Services Offered 142

13.9.4 Key Developments 142

13.9.5 SWOT Analysis 142

13.9.6 Key Strategy 142

13.10 Sanofi 143

13.10.1 Company Overview 143

13.10.2 Financial Overview 143

13.10.3 Products/Services Offered 144

13.10.4 Key Developments 144

13.10.5 SWOT Analysis 144

13.10.6 Key Strategy 144

13.11 Janssen Global Services LLC 145

13.11.1 Company Overview 145

13.11.2 Financial Overview 145

13.11.3 Products/Services Offered 146

13.11.4 Key Developments 146

13.11.5 SWOT Analysis 146

13.11.6 Key Strategy 146

13.12 Alexion Pharmaceuticals Inc. 147

13.12.1 Company Overview 147

13.12.2 Financial Overview 147

13.12.3 Products/Services Offered 148

13.12.4 Key Developments 148

13.12.5 SWOT Analysis 148

13.12.6 Key Strategy 148

13.13 Vertex Pharmaceuticals Inc. 149

13.13.1 Company Overview 149

13.13.2 Financial Overview 149

13.13.3 Products/Services Offered 150

13.13.4 Key Developments 150

13.13.5 SWOT Analysis 150

13.13.6 Key Strategy 150

13.14 Pfizer Inc. 151

13.14.1 Company Overview 151

13.14.2 Financial Overview 151

13.14.3 Products/Services Offered 152

13.14.4 Key Developments 152

13.14.5 SWOT Analysis 152

13.14.6 Key Strategy 152

13.15 Bristol Meyer Squibb 153

13.15.1 Company Overview 153

13.15.2 Financial Overview 153

13.15.3 Products/Services Offered 154

13.15.4 Key Developments 154

13.15.5 SWOT Analysis 154

13.15.6 Key Strategy 154

14 Appendix

14.1 Discussion Blue Print 156

15 List of Tables

TABLE 1 MARKET SYNOPSIS 16

TABLE 2 PRIMARY INTERVIEWS 21

TABLE 3 GLOBAL ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 36

TABLE 4 GLOBAL ORPHAN DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2030 (USD MILLION) 36

TABLE 5 GLOBAL ORPHAN DRUGS MARKET FOR NON-BIOLOGICS, BY REGION, 2022-2030 (USD MILLION) 37

TABLE 6 GLOBAL ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 40

TABLE 7 GLOBAL ORPHAN DRUGS MARKET FOR GENERICS, BY REGION, 2022-2030 (USD MILLION) 40

TABLE 8 GLOBAL ORPHAN DRUGS MARKET FOR PRESCRIBED, BY REGION, 2022-2030 (USD MILLION) 41

TABLE 9 GLOBAL ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 44

TABLE 10 GLOBAL ORPHAN DRUGS MARKET FOR REVLIMID, BY REGION, 2022-2030 (USD MILLION) 45

TABLE 11 GLOBAL ORPHAN DRUGS MARKET FOR RITUXAN, BY REGION, 2022-2030 (USD MILLION) 45

TABLE 12 GLOBAL ORPHAN DRUGS MARKET FOR OPDIVO, BY REGION, 2022-2030 (USD MILLION) 46

TABLE 13 GLOBAL ORPHAN DRUGS MARKET FOR KEYTRUDA, BY REGION, 2022-2030 (USD MILLION) 46

TABLE 14 GLOBAL ORPHAN DRUGS MARKET FOR IMBRUVICA, BY REGION, 2022-2030 (USD MILLION) 47

TABLE 15 GLOBAL ORPHAN DRUGS MARKET FOR SOLIRIS, BY REGION, 2022-2030 (USD MILLION) 47

TABLE 16 GLOBAL ORPHAN DRUGS MARKET FOR JAKAF, BY REGION, 2022-2030 (USD MILLION) 48

TABLE 17 GLOBAL ORPHAN DRUGS MARKET FOR POMALYST, BY REGION, 2022-2030 (USD MILLION) 48

TABLE 18 GLOBAL ORPHAN DRUGS MARKET FOR DARZALEX, BY REGION, 2022-2030 (USD MILLION) 49

TABLE 19 GLOBAL ORPHAN DRUGS MARKET FOR SPINRAZA, BY REGION, 2022-2030 (USD MILLION) 49

TABLE 20 GLOBAL ORPHAN DRUGS MARKET FOR ADCETRIS, BY REGION, 2022-2030 (USD MILLION) 50

TABLE 21 GLOBAL ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 53

TABLE 22 GLOBAL ORPHAN DRUGS MARKET FOR ONCOLOGY, BY REGION, 2022-2030 (USD MILLION) 54

TABLE 23 GLOBAL ORPHAN DRUGS MARKET FOR BLOOD, BY REGION, 2022-2030 (USD MILLION) 54

TABLE 24 GLOBAL ORPHAN DRUGS MARKET FOR CENTRAL NERVOUS SYSTEMS, BY REGION, 2022-2030 (USD MILLION) 55

TABLE 25 GLOBAL ORPHAN DRUGS MARKET FOR ENDOCRINE, BY REGION, 2022-2030 (USD MILLION) 55

TABLE 26 GLOBAL ORPHAN DRUGS MARKET FOR CARDIOVASCULAR, BY REGION, 2022-2030 (USD MILLION) 56

TABLE 27 GLOBAL ORPHAN DRUGS MARKET FOR RESPIRATORY, BY REGION, 2022-2030 (USD MILLION) 56

TABLE 28 GLOBAL ORPHAN DRUGS MARKET, BY REGION, 2022-2030 (USD MILLION) 58

TABLE 29 AMERICAS: ORPHAN DRUGS MARKET, BY REGION, 2022-2030 (USD MILLION) 61

TABLE 30 AMERICAS: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 61

TABLE 31 AMERICAS: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 61

TABLE 32 AMERICAS: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 62

TABLE 33 AMERICAS: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 63

TABLE 34 NORTH AMERICA: ORPHAN DRUGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 63

TABLE 35 NORTH AMERICA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 64

TABLE 36 NORTH AMERICA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 64

TABLE 37 NORTH AMERICA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 65

TABLE 38 NORTH AMERICA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 66

TABLE 39 US: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 66

TABLE 40 US: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 67

TABLE 41 US: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 67

TABLE 42 US: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 68

TABLE 43 CANADA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 68

TABLE 44 CANADA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 69

TABLE 45 CANADA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 69

TABLE 46 CANADA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 70

TABLE 47 LATIN AMERICA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 70

TABLE 48 LATIN AMERICA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 71

TABLE 49 LATIN AMERICA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 71

TABLE 50 LATIN AMERICA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 72

TABLE 51 EUROPE: ORPHAN DRUGS MARKET, BY REGION, 2022-2030 (USD MILLION) 73

TABLE 52 EUROPE: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 74

TABLE 53 EUROPE: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 74

TABLE 54 EUROPE: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 75

TABLE 55 EUROPE: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 76

TABLE 56 WESTERN EUROPE: ORPHAN DRUGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 77

TABLE 57 WESTERN EUROPE: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 78

TABLE 58 WESTERN EUROPE: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 78

TABLE 59 WESTERN EUROPE: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 79

TABLE 60 WESTERN EUROPE: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 80

TABLE 61 GERMANY: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 80

TABLE 62 GERMANY: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 81

TABLE 63 GERMANY: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 81

TABLE 64 GERMANY: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 82

TABLE 65 FRANCE: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 83

TABLE 66 FRANCE: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 83

TABLE 67 FRANCE: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 84

TABLE 68 FRANCE: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 85

TABLE 69 UK: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 85

TABLE 70 UK: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 86

TABLE 71 UK: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 86

TABLE 72 UK: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 87

TABLE 73 ITALY: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 87

TABLE 74 ITALY: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 88

TABLE 75 ITALY: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 88

TABLE 76 ITALY: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 89

TABLE 77 SPAIN: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 89

TABLE 78 SPAIN: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 90

TABLE 79 SPAIN: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 90

TABLE 80 SPAIN: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 91

TABLE 81 REST OF WESTERN EUROPE: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 91

TABLE 82 REST OF WESTERN EUROPE: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 92

TABLE 83 REST OF WESTERN EUROPE: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 92

TABLE 84 REST OF WESTERN EUROPE: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 93

TABLE 85 EASTERN EUROPE: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 94

TABLE 86 EASTERN EUROPE: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 94

TABLE 87 EASTERN EUROPE: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 95

TABLE 88 EASTERN EUROPE: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 96

TABLE 89 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 98

TABLE 90 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 98

TABLE 91 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 99

TABLE 92 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 99

TABLE 93 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 100

TABLE 94 JAPAN: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 100

TABLE 95 JAPAN: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 101

TABLE 96 JAPAN: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 101

TABLE 97 JAPAN: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 102

TABLE 98 CHINA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 102

TABLE 99 CHINA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 103

TABLE 100 CHINA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 103

TABLE 101 CHINA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 104

TABLE 102 INDIA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 104

TABLE 103 INDIA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 105

TABLE 104 INDIA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 105

TABLE 105 INDIA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 106

TABLE 106 SOUTH KOREA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 106

TABLE 107 SOUTH KOREA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 107

TABLE 108 SOUTH KOREA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 107

TABLE 109 SOUTH KOREA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 108

TABLE 110 AUSTRALIA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 108

TABLE 111 AUSTRALIA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 109

TABLE 112 AUSTRALIA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 109

TABLE 113 AUSTRALIA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 110

TABLE 114 REST OF ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 110

TABLE 115 REST OF ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 111

TABLE 116 REST OF ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 111

TABLE 117 REST OF ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 112

TABLE 118 MIDDLE EAST AND AFRICA: ORPHAN DRUGS MARKET, BY REGION, 2022-2030 (USD MILLION) 113

TABLE 119 MIDDLE EAST AND AFRICA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 114

TABLE 120 MIDDLE EAST AND AFRICA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 114

TABLE 121 MIDDLE EAST AND AFRICA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 115

TABLE 122 MIDDLE EAST AND AFRICA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 116

TABLE 123 MIDDLE EAST: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 116

TABLE 124 MIDDLE EAST: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 117

TABLE 125 MIDDLE EAST: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 117

TABLE 126 MIDDLE EAST: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 118

TABLE 127 AFRICA: ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION) 118

TABLE 128 AFRICA: ORPHAN DRUGS MARKET, BY SALE, 2022-2030 (USD MILLION) 119

TABLE 129 AFRICA: ORPHAN DRUGS MARKET, BY DRUG, 2022-2030 (USD MILLION) 119

TABLE 130 AFRICA: ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022-2030 (USD MILLION) 120

16 List of Figures

FIGURE 1 GLOBAL ORPHAN DRUGS MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ORPHAN DRUGS MARKET 26

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS OF GLOBAL ORPHAN DRUGS MARKET 31

FIGURE 6 SUPPLY CHAIN: ORPHAN DRUGS MARKET 33

FIGURE 7 GLOBAL ORPHAN DRUGS MARKET SHARE, BY DRUG TYPE, 2022 (%) 35

FIGURE 8 GLOBAL ORPHAN DRUGS MARKET, BY DRUG TYPE, 2022 & 2030 35

FIGURE 9 GLOBAL ORPHAN DRUGS MARKET SHARE, BY SALE, 2022 (%) 39

FIGURE 10 GLOBAL ORPHAN DRUGS MARKET, BY SALE, 2022 & 2030 39

FIGURE 11 GLOBAL ORPHAN DRUGS MARKET SHARE, BY DRUG, 2022 (%) 43

FIGURE 12 GLOBAL ORPHAN DRUGS MARKET, BY DRUG, 2022 & 2030 44

FIGURE 13 GLOBAL ORPHAN DRUGS MARKET SHARE, BY THERAPY CLASS, 2022 (%) 52

FIGURE 14 GLOBAL ORPHAN DRUGS MARKET, BY THERAPY CLASS, 2022 & 2030 53

FIGURE 15 GLOBAL ORPHAN DRUGS MARKET, BY REGION, 2022 & 2030 (USD MILLION) 58

FIGURE 16 GLOBAL ORPHAN DRUGS MARKET SHARE, BY REGION, 2022 (%) 59

FIGURE 17 AMERICAS: ORPHAN DRUGS MARKET SHARE, BY REGION, 2022 (%) 60

FIGURE 18 EUROPE: ORPHAN DRUGS MARKET SHARE, BY REGION, 2022 (%) 73

FIGURE 19 WESTERN EUROPE ORPHAN DRUGS MARKET SHARE, BY COUNTRY, 2022 (%) 77

FIGURE 20 ASIA-PACIFIC: ORPHAN DRUGS MARKET SHARE, BY COUNTRY, 2022 (%) 97

FIGURE 21 MIDDLE EAST AND AFRICA: ORPHAN DRUGS MARKET SHARE, BY REGION, 2022 (%) 113

FIGURE 22 GLOBAL ORPHAN DRUGS MARKET SHARE ANALYSIS 2022 (%) 122

FIGURE 23 GLOBAL ORPHAN DRUGS MARKET COMPETITIVE LANDSCAPE 2022 (%) 123

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Press Release
pr-img
The increasing cases of rare diseases and the development of innovative medicines through technol...
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)